Latest:
Cosmo Smith on The Breakthrough Oncology Accelerator Flagship Program
P. Cosmo Smith, MBA, managing partner, Origin Commercial Ventures, discusses The Breakthrough Oncology Accelerator flagship program.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Padmanee Sharma, MD, PhD
Latest:
Dr. Sharma Discusses Immune Checkpoint Resistance in GU Cancers
Padmanee Sharma, MD, PhD, professor of Immunology in the Department of Genitourinary Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses immune checkpoint resistance in genitourinary cancers.
Pamela Munster, MD
Latest:
Dr. Munster on Vorinostat Plus Tamoxifen for Breast Cancer
Pamela Munster, MD, from UCSF Helen Diller Family Comprehensive Cancer Center, discusses results from a phase II study that examined vorinostat in combination with tamoxifen for endocrine therapy-resistant breast cancer.
Pamela N. Munster, MD
Latest:
Dr. Munster on Developing Biosimilars
Pamela N. Munster, MD, professor, department of medicine (hematology/oncology), University of California, San Francisco (UCSF), director, early phase clinical trials unit, co-leader, Center for BRCA Research, leader, Experimental Therapeutics Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses the developmental process for biosimilars in oncology.
Pamela R. Soulos, MPH
Latest:
Changes in Prostate Cancer Presentation for Radiation Oncology Care
USPSTF guidelines may have decreased the number of patients presenting with prostate
cancer for radiation oncology care, particularly those with low-risk disease, without a
short-term increase in higher-risk disease.
Panagiotis A. Konstantinopoulos, MD
Latest:
Dr. Konstantinopoulos on the Phase III Results of the JAVELIN 200 Trial in Ovarian Cancer
Panagiotis A. Konstantinopoulos, MD, director, Translational Research, Gynecologic Oncology, Dana-Farber Cancer Institute, associate professor of medicine, Harvard Medical School, discusses the disappointing results of the JAVELIN 200 trial in ovarian cancer.
Panagiotis A. Konstantinopoulos, MD, PhD
Latest:
Dr. Konstantinopoulos on Immunotherapy in Ovarian Cancer
Panagiotis A. Konstantinopoulos, MD, PhD, director of Translational Research, Gynecologic Oncology, Dana-Farber Cancer Institute, associate professor of medicine, Harvard Medical School, discusses the role of immunotherapy in the treatment of patients with ovarian cancer.